Compare T & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | T | NVO |
|---|---|---|
| Founded | 1983 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5B | 166.1B |
| IPO Year | N/A | N/A |
| Metric | T | NVO |
|---|---|---|
| Price | $24.19 | $44.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | $30.55 | ★ $51.00 |
| AVG Volume (30 Days) | ★ 29.8M | 14.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.31% | 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $2.14 | $3.70 |
| P/E Ratio | ★ $9.14 | $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.95 | $35.12 |
| 52 Week High | $29.79 | $81.44 |
| Indicator | T | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 30.34 | 58.43 |
| Support Level | $24.14 | $43.16 |
| Resistance Level | $26.21 | $50.30 |
| Average True Range (ATR) | 0.50 | 1.11 |
| MACD | -0.10 | 0.13 |
| Stochastic Oscillator | 0.00 | 61.31 |
The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 12% of revenue, primarily consist of broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 24 million customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.